



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 9896.129.3.1.1

CHUDZIK, et al.

Application No.: 09/989,033

Examiner: Bret P. Chen

Filed: November 21, 2001

Group Art Unit: 1762

For: BIOACTIVE AGENT RELEASE COATING

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination under 37 C.F.R. § 1.114 and an Electronic Information Disclosure Statement. The Electronic Information Disclosure Statement, with U.S. patent references, includes our request to the Commissioner to charge our Deposit Account the amount of \$180.00 for filing fees set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c)). Therefore, the Supplemental Information Disclosure Statement and the

Electronic Information Disclosure Statement should be considered as a single disclosure and thereby require no additional fee.

JP 0919437 is a Japanese-language reference. An English-language abstract for this reference is provided. JP 2036882 is a Japanese-language reference. An English-language abstract for this reference is provided. JP 08033718 is a Japanese-language reference. An English-language abstract for this reference is provided. JP 09099056 is a Japanese-language reference. An English-language abstract for this reference is provided. WO 00/55396 is a Japanese-language reference. An English-language abstract for this reference is provided.

By submitting these references, Applicant does not admit that the references are prior art to or material to this application, and reserves the right to establish that any reference is not prior art. Applicant does not represent that the references have been reviewed in detail; there may be details in the references of which Applicant is unaware.

Respectfully submitted,



John F. Dolan
Registration No. 45,382


Customer No. 22859
Fredrikson & Byron, P.A.
200 South Sixth Street, Suite 4000
Minneapolis, MN 55402-1425 USA
Telephone: (612) 492-7000
Facsimile: (612) 492-7077


Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 06-1910.


CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on

December 8, 2004
Date of Deposit


Joleen R. Krueger

 <p style="margin: 0;">INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
				APPLICANT Chudzik et al.			
				FILING 21 November 2001		GROUP 1762	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		EP 0 706 376 B1	6/1997	EP			
		EP 0 923 953 A2	6/1999	EP			
		JP 2036882	2/1990	JP			
		JP 08033718A	2/1996	JP			
		JP 09099056A	4/1997	JP			
		JP 09194347A	7/1997	JP			
		WO 88/02623	4/1988	WO			
		WO 89/05616	6/1989	WO			
		WO 90/00887	2/1990	WO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Brown LR, Edelman ER, Fischel-Ghodsian F, Langer R, Characterization of glucose-mediated insulin release from implantable polymers, Pharm Sci 1996 Dec; 85 (12): 1341-5.					
		Catz P, Friend DR, In vitro evaluations of transdermal levonorgestrel, Drug Des Deliv, 1990, May; 6 (1): 49-60.					
		Edelman ER, Simons M, Sirois MG, Rosenberg RD, c-myc in vasculoproliferative disease, Circ Res 1995 Feb; 76(2): 176-82.					
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/03990	4/1991	WO				
	WO 91/10424	7/1991	WO				
	WO 93/16176	8/1993	WO				
	WO 94/11032	5/1994	WO				
	WO 94/21309	9/1994	WO				
	WO 96/37165	11/1996	WO				
	WO 96/39821	12/1996	WO				
	WO 97/16544	5/1997	WO				
	WO 97/34935	9/1997	WO				
	WO 99/08717	2/1999	WO				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Eliaz R, Wallach D, Kost J, Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor, Cytokine, 1996, Jun; 8(6): 482-7.
	Flemmig TF, Weinacht S, Rudiger S, Rumetsch M, Jung A, Klaiber B, Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid, J Chin Periodontol 1996 OCT; 23 (10):914-21.
	Folkman J, How the field of controlled-release technology began, and its central role in the development of angiogenesis research, Biomaterials, 1990, Nov; 11 (9): 615-8.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p style="margin: 0;">INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
				APPLICANT Chudzik et al.			
				FILING 21 November 2001		GROUP 1762	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		WO 99/16907	4/1999	WO			
		WO 99/43688	9/1999	WO			
		WO 99/47129	9/1999	WO			
		WO 99/47176	9/1999	WO			
		WO 99/64086	12/1999	WO			
		WO 00/12163	3/2000	WO			
		WO 00/40593	7/2000	WO			
		WO 00/55396	9/2000	WO			
		WO 01/21326	3/2001	WO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Friling R, Yassar Y, Levy R, Kost J. Schwartz B, Mikhailowsky R, Lamprecht SA, A role of transforming growth factor-beta 1 in the control of corneal neovascularization, In Vivo 10, 59-64 (1996).					
		Goodson JM, Hogan PE, Dunham SL, Clinical responses following periodontal treatment by local drug delivery, J Periodontal 1985 Nov; 56 (11 Suppl): 81-7.					
		Huland E, Falk B, Hubner D, Huland H, In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors, Int. J. Cancer, 1995, 62, 605-9.					
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

 <p style="text-align: center;">INFORMATION DISCLOSURE CITATION</p> <p style="text-align: center;">(Use several sheets if necessary)</p>	ATTY. DOCKET NO. 9896.129.3.1.1	SERIAL NO. 09/989,033
	APPLICANT Chudzik et al.	
	FILING 21 November 2001	GROUP 1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 01/36008	5/2001	WO				
WO 01/44174	6/2001	WO				
WO 01/66161	9/2001	WO				
WO 01/87342	11/2001	WO				
WO 01/87372	11/2001	WO				
WO 01/87373	11/2001	WO				
WO 01/87374	11/2001	WO				
WO 01/87375	11/2001	WO				
WO 01/87376	11/2001	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Lees VC, Fan TP, West DC, Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan, Lab Invest, 1995, 73, 259-66.
		Lesser GJ, Grossman SA, Leong KW, et al., In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain, Pain, 1996, May-Jun; 65 (2-3): 265-72.
		Lopez JJ, Edelman ER, Stamler A, et al., Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia, Am J Physiol 1998 Mar; 274 (3 Pt 2): H930.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
				APPLICANT Chudzik et al.			
				FILING 21 November 2001		GROUP 1762	

OIPE
 DEC 13 2004
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
	WO 02/26139	4/2002	WO					
	WO 02/26271	4/2002	WO					
	WO 02/26281	4/2002	WO					
	WO 03/022323	3/2003	WO					
	WO 03/064015	8/2003	WO					
	WO 04/000267	12/2003	WO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Ozaki H, Hayashi H, Vinorel SA, Moromizato Y, Campochiaro PA, Oshima K, Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates, Exp Eye Res, 1997, 64, 505-17.
	Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M, Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia, Surgery 1996 Aug; 120 (2): 182-8.
	Suzuki, T. et al. Stent-based delivery of sivolimus release. Circulation 2001, 104: 1188-1193.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Jafary, F, et al Point-Counterpoint: Drug Eluting Stent Euphoria
	Morice et al, A Randomized Comparison of a Sirolimus-Eluting Stent, N Engl J Med, 2002 June; 346, 1773-1780
	Raman et al, Coated Stents: Local Pharmacology, Semin Intervent Cardiol 1998: 3: 133-137

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>					ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
					APPLICANT Chudzik et al.			
					FILING 21 November 2001		GROUP 1762	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Whelan et al, Mechanisms of Drug Loading and Release Kinetics, Semin Intervent Cardiol 1998; 3: 127-131
		Klugherz et al, Twenty-eight-day Efficacy and Phamacokinetics, Coronary Artery Disease 2002 13 (3)
		Regar et al, Stent Development and Local Drug Delivery, British Med Bulletin 2001; 59: 227-48

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

